Catalog No.: PC-63308Not For Human Use, Lab Use Only.
Zotatifin (eFT226) is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.
Zotatifin (eFT226) is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.
Zotatifin (eFT226) selectively inhibits translation of mRNAs containing longer 5'-UTRs, an increased frequency of uORFs (upstream open reading frame), and polypurine and/or G-quadraplex recognition motifs.
Zotatifin (eFT226) demonstrates potent inhibition of reporter constructs containing a polypurine motif in the 5'-UTR with IC50 of 2 nM.
Zotatifin (eFT226) shows potent anti-proliferative activity (EC50<15 nM) and an induction of apoptosis against a panel of B-cell lymphoma cell lines, dose-dependently decreases the oncogenic drivers c-MYC, CCND1/3, BCL2 or MCL-1.
Zotatifin (eFT226) shows in vivo activity across hematological tumor models.
1. Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.
